Australian medical device company Sirtex Medical Limited (ASX: SRX) announced today that its board of directors has recommended acceptance of a A$1.87 billion (US$1.4 billion) acquisition proposal by Chinese alternative asset fund manager CDH Investments.
Yaoshibang, a Guangzhou-based online pharmacy trading and education platform, announced that it has completed a RMB420 million (US$65.7 million) series C round led by Shunwei Capital and DCM Ventures.
Shanghai-based pharmaceutical and medical device firm WuXi AppTec has led a strategic funding round in Insilico Medicine, a Baltimore-based artificial intelligence company specializing in the application of deep learning for target identification, drug discovery and aging research.
WuXi Biologics (2269.HK), an open-access biologics technology company based in China, is to invest US$60 million and hire approximately 150 employees to establish a biologics clinical and commercial manufacturing facility in Worcester, Massachusetts in the United States. The facility will be WuXi Biologics’ 11th global drug substance manufacturing facility, the firm said today in an announcement.
Beijing and Hong Kong-based investment firm Hillhouse Capital has led a US$35 million series B+ round in antibody and recombinant protein biotherapeutics firm Hangzhou Just Biotherapeutics (HJB).
China’s Zhejiang Silk Road Fund has participated in a US$100 million series B round in CMR Surgical Ltd, a British company developing surgical robots.
Chinese alternative asset fund manager CDH Investments and Beijing-based Leadyond Capital have led a RMB250 million (US$39 million) series B round in Chengdu-based drug discovery firm HitGen, according to HitGen’s announcement.
Pivotal bioVenture Partners China (Pivotal China), a member of Nan Fung Life Sciences announced the closing of Pivotal bioVenture Partners China USD Fund I, raising US$150 million to incubate and build life sciences companies in China.
China and US-headquartered biomedical firm Brii Bio has raised US$260 million from Sequoia Capital, Yunfeng Capital and others.
GIC, the Singapore investment firm managing the state’s foreign reserves, has led a US$260 million (RMB1.653 billion) series B financing in CStone, a Chinese bio-pharmaceutical company.
Tencent-backed online healthcare service provider We Doctor Holdings has completed a US$500 million Pre-IPO round led by AIA Company Ltd, part of Hong Kong-listed insurer AIA Group and NWS Holdings Ltd., valuing the firm at US$5.5 billion.
Ascletis Pharma, a Hangzhou-based biotechnology firm, has filed to list on the Hong Kong Stock Exchange, making it the first company to exploit the new and more accommodating listing rules in the city, an IPO prospectus published by the Hong Kong Stock Exchange showed. Ascletis Pharma Inc. focuses on three therapeutic areas: anti-viral, cancer and fatty liver diseases. It operates an integrated anti-viral platform focused on developing and commercializing innovative drugs against HCV, HIV and HBV. Currently, the company operates …
Chinese alternative asset fund manager CDH Investments has proposed to acquire Australian medical device company Sirtex Medical Limited (ASX: SRX) for about A$1.87 billion (US$1.4 billion), according to Sirtex Medical’s announcement today. Sirtex Medical said it had received an unsolicited non-binding, indicative and conditional proposal from CDH Investments to acquire 100% of its shares for a cash price of A$33.6 per share, representing a 14.2% premium over its closing price of A$29.42. With 55.77 million shares outstanding, Sirtex Medical is …
Venture capital firm GGV Capital has led a RMB100 million (US$15.7 million) series B round in Shanghai-based artificial intelligence-powered medical data solutions provider Synyi.
Capital Group Private Markets, a unit of U.S. investment firm Capital Group Companies, has led a US$150 million round in Chinese biotech firm Innovent Biologics, Inc.
Alibaba-backed genetic testing and digital health company Prenetics has acquired UK-based consumer genetic testing firm DNAFit, the latest in a series of Chinese investments in U.K healthcare assets.
Chinese orthopaedic implant company AK Medical Holdings Limited has announced the acquisition of JRI Orthopaedics Limited, a U.K. firm that designs, manufactures and supplies orthopaedic implants and related instruments, from Orthopaedic Research UK for £16.73 million (US$23.7 million).
CMB International Capital Corporation Ltd, a wholly-owned subsidiary of China Merchants Bank, has led a RMB410 million (US$65 million) series C round in Beijing Biocytogen Co., Ltd., a gene targeted animal model and service supplier.
Chinese specialty hospital management solution provider Concord Medical Services Holdings Limited (NYSE: CCM), has announced that CICC Capital Management Company Limited, a wholly-owned subsidiary of China International Capital Corporation Limited, will lead a strategic investment of between RMB1.5 billion (US$238.5 million) and RMB1.8 billion (US$286.16 million) in Concord Medical’s subsidiary Beijing Meizhong Jiahe Hospital Management Co., Ltd.
James Watson, the Nobel laureate who co-discovered the structure of DNA, has thrown his support behind a life science research center being established by the Shenzhen city government. In fact, the 90-year-old scientist will work at the facility, according to Chinese media.
Chinese healthcare provider iKang Healthcare Group, Inc. (NASDAQ:KANG）announced that a consortium led by Alibaba Investment Limited and Jack Ma co-founded Yunfeng Capital, has proposed a all-cash transaction to privatize the US$1.29 billion company.
Chinese cell therapy company JW Therapeutics (Shanghai) Co., Ltd announced that it has raised a US$90 million series A found led by investors Temasek, Sequoia Capital China, and YuanMing Capital, a Beijing-based US dollar fund focusing on investments in pharmaceutical research and development, medical devices and services in both China and the U.S.
Matrix Partners China, a joint venture fund between U.S. venture capital firm Matrix Partners and its Chinese partners, has led a RMB100 million (US$15.8 million) financing round in Chinese genetics testing and analyzing start-up 23Mofang.
U.S.-based cancer detection start-up Grail Inc. is reportedly planning an initial public offering on the Hong Kong Stock Exchange in what could be the first test of the city’s proposed duel-class listing system for tech companies.
Fosun International Ltd. (00656:HK) and London-based healthcare and life science company Arix Bioscience plc (LSE:ARIX) have jointly announced a strategic agreement to develop and commercialize new clinical therapies for patients with a focus on the Chinese markets.
Citic Capital-controlled Harbin Pharmaceutical Group Holding, known as Hayao, has agreed to invest US$300 million in U.S.-based health and wellness retailer GNC Holdings, becoming the single largest shareholder in NYSE-traded GNC.
American nutrition supplements company Herbalife Ltd. announced today it has created a “China Growth and Impact Investment Fund” to accelerate growth of its business in China.
U.S. pharmaceutical giant Pfizer has taken a financial stake and entered into a two-year research collaboration with NetVation DL Medicine, a privately held biotechnology company that is backed by Chinese Academy of Sciences.
Ping An Healthcare And Technology Co., Ltd., which operates the popular healthcare and medical mobile app Ping An Good Doctor, has been cleared for a US$5 billion initial public offering in Hong Kong.
Ping An Ventures, the direct investment arm of Ping An Insurance (Group) Company of China, Ltd., has led a US$100 million series A round in Philadelphia-based biotherapeutics company Tmunity Therapeutics.
Chinese investment banking firm CEC Capital Group has announced the promotion of John Song, Gang Li and Zack Zhang to partner, as the firm aims to broaden and deepen its coverage to a new class of rising Chinese enterprises.